Literature DB >> 12558466

NICE methodological guidelines and decision making in the National Health Service in England and Wales.

Amiram Gafni1, Stephen Birch.   

Abstract

The National Institute for Clinical Excellence (NICE) responds to requests by the Department of Health for guidance on the use of selected new and established technologies in the National Health Service (NHS) in England and Wales. This paper asks whether the NICE methodological guidelines help NHS decision makers meet the objectives of maximum health improvements from NHS resources and an equitable availability of technologies. The analytical basis of the guidelines is a comparison of the costs and consequences of new and existing methods of dealing with particular conditions using the incremental cost-effectiveness ratio. We explain why information on the costs and consequences of a particular technology in isolation is insufficient to address issues of efficiency of resource use. We argue that to increase efficiency, decision makers need information on opportunity costs. We show that in the absence of such information decision makers cannot identify the efficient use of resources. Finally we argue that economics provides valid methods for identifying the maximisation of health improvements for a given allocation of resources and we describe an alternative practical approach to this problem. Drawing on the experience of Ontario, Canada where an approach similar to that proposed by NICE has been in use for almost a decade, and recent reports about the consequences of NICE decisions to date, we conclude that instead of increasing the efficiency or equity of the use of NHS resources, NICE methodological guidelines may lead to: uncontrolled increases in NHS expenditures without evidence of any increase in total health improvements; increased inequities in the availability of services; and concerns about the sustainability of public funding for new technologies.

Mesh:

Year:  2003        PMID: 12558466     DOI: 10.2165/00019053-200321030-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

1.  A nice challenge for health economics.

Authors:  J Hutton; A Maynard
Journal:  Health Econ       Date:  2000-03       Impact factor: 3.046

2.  Opportunity costs and uncertainty in the economic evaluation of health care interventions.

Authors:  P Sendi; A Gafni; S Birch
Journal:  Health Econ       Date:  2002-01       Impact factor: 3.046

3.  Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

Authors:  Andreas Laupacis
Journal:  CMAJ       Date:  2002-01-08       Impact factor: 8.262

4.  On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.

Authors:  Stephen Birch; Amiram Gafni
Journal:  Health Econ       Date:  2002-04       Impact factor: 3.046

5.  Wrong SIGN, NICE mess: is national guidance distorting allocation of resources?

Authors:  R Cookson; D McDaid; A Maynard
Journal:  BMJ       Date:  2001-09-29

6.  Effectiveness, efficiency, and NICE.

Authors:  M Sculpher; M Drummond; B O'Brien
Journal:  BMJ       Date:  2001-04-21

7.  Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems.

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1993-12       Impact factor: 3.883

Review 8.  Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1992-10       Impact factor: 3.883

9.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1992-02-15       Impact factor: 8.262

10.  Cost-effectiveness analysis: are the outputs worth the inputs?

Authors:  D Naylor
Journal:  ACP J Club       Date:  1996 Jan-Feb
View more
  14 in total

1.  The NICE reference case requirement: more pain for what, if any, gain?

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal.

Authors:  Christopher Evans; Manouche Tavakoli; Bruce Crawford
Journal:  Health Care Manag Sci       Date:  2004-02

3.  Breadth, Depth and Agreement among Provincial Formularies in Canada.

Authors:  Steve Morgan; Gillian Hanley; Colette Raymond; Régis Blais
Journal:  Healthc Policy       Date:  2009-05

4.  Persisting without Evidence is a Problem: Suicide Prevention and Other Well-Intentioned Interventions.

Authors:  John D McLennan
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2015-08-31

5.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lieven Annemans; Mickael Löthgren; Gabriele Allegri; Veronique Wyffels; Lindsay Hemmet; Karin Caekelbergh; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  QALYs: are they helpful to decision makers?

Authors:  Maurice McGregor; J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 7.  Information created to evade reality (ICER): things we should not look to for answers.

Authors:  Stephen Birch; Amiram Gafni
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

8.  Building bridges between academic research and policy formulation: when costing less means costing more.

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 9.  Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1.

Authors:  Maria Buti; Miguel A Casado; Leslie Fosbrook; Rafael Esteban
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 10.  Catalyzing the Translation of Patient-Centered Research Into United States Trauma Care Systems: A Case Example.

Authors:  Douglas Zatzick; Kathleen Moloney; Lawrence Palinkas; Peter Thomas; Kristina Anderson; Lauren Whiteside; Deepika Nehra; Eileen Bulger
Journal:  Med Care       Date:  2021-08-01       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.